Teva CEO says manufacturing cuts will keep coming even after $3B reduction achieved

Kåre Schultz
Teva CEO Kåre Schultz has plans for further efficiencies in manufacturing. (News Oresund/CC BY 2.0)

The way Teva Pharmaceutical CEO Kåre Schultz figures it, manufacturing is the cost-cutting gift that just keeps on giving. After the Israeli drugmaker completes its declared $3 billion cost reduction effort, it can still look to manufacturing efficiencies to build its margin. 

Schultz laid out the blueprint last week during a conference call in which the company reported a much larger quarterly net loss but told investors progress continues to be made. He said the company has cut $2.7 billion in operating expenses since it instituted its plan in 2018. 

RELATED: Teva, amid massive restructuring, closes in on $3B cost-cutting goal


Survey: The Critical Role of Innovation in Launching Successful OTC Products

This research aims to understand the importance of product innovation and dose forms in driving new product design and development, consumer engagement and purchase interest for Over-the-Counter medicines. The first 50 qualified respondents will receive a $5 Amazon gift card. Take the survey now.

Schultz said the company expects to swell its margin to 27% from its current 23% through improvements in its product mix and making manufacturing more efficient.

“Now, we are not going to do a big splash restructuring, but we will do ongoing optimization of our manufacturing footprint,” Schultz said, according to a transcript of the call from Seeking Alpha. “I said before and I'll repeat now, that once the restructuring program is fully executed, which will be at the end of this year, then we will share with you our longer term plans for how to optimize manufacturing going forward.”  

The CEO said experience tells him the company can achieve incremental improvements over time, say, improvements of 50 basis points to 100 basis points a year.

 RELATED: Teva's stunning list of cuts targets 14K jobs, $3B in costs and plants around the globe 

“It doesn't come linearly, because you do have some step changes when you change your manufacturing footprint or when you launch products in more markets and so on,” Schultz said. “And it's a long-term commitment, where you keep on doing this. It's thousands of different activities and changes you do, but it's a sustainable improvement methodology and I believe that we'll be able to do that going forward.”

The drugmaker has made substantial business amputations since Schultz was hired in 2017 to clean up a disjointed and inefficient business that was failing after making some huge, and ill-timed, M&A bets that flopped. Teva has settled lawsuits and closed offices and manufacturing facilities while laying off thousands of employees. 

Just last month, it sold its U.S. portfolio of OTC products and a 93,000-square-foot manufacturing facility in Copiague, New York, to privately owned PL Developments. The plant has about 80 employees.

Suggested Articles

With drug-resistant bacteria on the rise, antibiotics have struggled to keep up. But with an FDA nod for Nabriva's Xenleta, some of that may change.

JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.

Rather than "we did the best we could," Vas Narasimhan, during an internal call with managers, said Novartis could have handled the Zolgensma crisis…